Health
Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results
CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed several encouraging results that suggest real potential for patients living with this rare disease. While the trial (conducted in 268 patients in the U.S., Europe, Japan, and Brazil) did not achieve the primary goal of reducing oral cortic
About this update from Atyr Pharma, Inc.
[{"type":"image","alt":"Foundation for Sarcoidosis Research","displaySize":"","headline":null,"caption":"Foundation for Sarcoidosis Research","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/79b5464b2112a86dcfd271ecb3cf0677"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ddi9uieKPpTx7ty56NoLww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/79b5464b2112a86dcfd271ecb3cf0677","width":300,"height":112}},"lazy":false},{"type":"text","content":"CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed several encouraging results that suggest real potential for patients living with this rare disease.","length":360,"tagName":"p"},{"type":"text","content":"While the trial (conducted in 268 patients in the U.S., Europe, Japan, and Brazil) did not achieve the primary goal of reducing oral corticosteroid use compared to placebo, findings for other study outcome measures suggest that efzofitimod helped more patients completely withdraw from steroids and improved measures of quality of life alongside stable lung function, with a favorable safety profile.","length":400,"tagName":"p"},{"type":"text","content":"“We greatly appreciate the patients with sarcoidosis and their families who generously participated in the EFZO-FIT™ study. Their commitment made it possible to further essential research aimed at improving understanding and treatment of sarcoidosis,” said Mary McGowan, President and CEO of FSR. “FSR also thanks the investigators, clinical teams, and research partners who supported this study. FSR remains committed to advancing innovative research and ensuring patient perspectives are central to future trial design and drug development efforts. We look forward to learning more as aTyr takes deeper dives into the robust trial data that will allow us to learn more about sarcoidosis.”","length":690,"tagName":"p"},{"type":"text","content":"FSR encourages all stakeholders—patients, researchers, drug development companies, and regulators—to build upon the knowledge generated from this clinical trial as the largest interventional...